Document is current
Any future updates will be listed below
-
Authors
Blauenfeldt, Rolf Ankerlund
Hess, David Charles
Gaist, David
Modrau, Boris
Valentin, Jan Brink
Johnsen, Søren Paaske
Hjort, Niels
Behrndtz, Anne Brink
Gude, Martin Faurholdt
Zhao, Wenbo
Jensen, Jonas
Andersen, Grethe
Simonsen, Claus Ziegler
-
Funding
Funding for this research was provided by:
TrygFonden (120636)
National Institute of Health (1R01NS112511-01A1)
Novo Nordisk Fonden (NNF00052924)
Manufacturer Vilhelm Pedersen and Wife’s foundation (NNF16OC0023474)
Aase and Ejnar Danielsens Foundation (10–002120)
Aarhus University Hospital
- License Information
-
More Information
Article History
Received: 10 June 2025
Revised: 14 August 2025
Accepted: 14 August 2025
First Online: 6 September 2025
Declarations
:
: The trial was approved by Danish regional research ethics committees (ID:1–10–72–97–17), The Data Protection Agency (ID: 1–16–02–16–18) and The Danish Medicines Agency (ID:2017114177, EUDAMED: CIV-17–11–022324) as an acute study. Consent was waived for the acute prehospital phase but was obtained from all patients, their relatives, or trial guardians as soon as possible after hospital arrival.
: The authors declare no competing interests.
: RB and GA.
